Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p176 | (1) | ICCBH2015

Evaluation of fibroblast growth factor 23 in patients with hypophosphataemic rickets

Park Julie , Khan Kursheed , Hatchard Lynne , Ramakrishnan Renuka , Senniappan Senthil , Fraser William , Dharmaraj Poonam

Objective: Hypophosphataemic rickets (HPR) is associated with high concentrations of fibroblast growth factor 23 (FGF23). Chronically elevated FGF23 may impact on cardiac function and the skeleton. There is little evidence on how FGF23 changes with time in HPR or how it is affected by treatment. The aim of this study was to evaluate changes in FGF23 concentrations over time in patients with HPR.Methods: Retrospective data was collected from our Metabolic...

ba0007p124 | (1) | ICCBH2019

Heterozygous CDC73 mutation causing parathyroid adenoma in an adolescent girl presenting with mental health issues

Mulvey Ian , Ramakrishnan Renuka , Dharmaraj Poonam , Abernethy Laurence , Jones Matthew , Senniappan Senthil

Background: Primary hyperparathyroidism (PH), whilst common in elderly populations, is much rarer in adolescents. Although up to 90% of cases are sporadic in nature, hereditary cases make up less than 10% of remaining causes. Multiple genetic causes and syndromes have been described in the literature including multiple endocrine neoplasia (MEN), familial hypocalciuric hypercalcemia and hyperparathyroidism-jaw tumour syndrome (HPT-JT).Presenting problem: ...

ba0004p105 | (1) | ICCBH2015

Refractory hypercalcaemia of malignancy: responsiveness to Denosumab and Zoledronate

Giri Dinesh , Ramakrishnan Renuka , Hayden James , Brook Lynda , Das Urmi , Mughal M Zulf , Selby Peter , Dharmaraj Poonam , Senniappan Senthil

Background: Hypercalcaemia secondary to malignancy is rare in children and adolescents. Parathyroid hormone related peptide (PTH-rP) secreted by malignant cells increases bone resorption and renal calcium retention causing hypercalcaemia. We report two cases of hypercalcaemia of malignancy refractory to treatment with pamidronate and corticosteroids but responsive to treatment with Denosumab and Zoledronic acid.Case 1: Presenting problem: A 17-year-old b...